First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.

Summary: We assessed the pharmacokinetics and safety of a single oral administration of selatinib to healthy Chinese subjects and evaluated the potential bioavailability advantage of selatinib relative to lapatinib. Healthy subjects aged 18–40 years were enrolled in this two-part study: Part 1, a si...

Full description

Bibliographic Details

Published in:	Investigational New Drugs Vol. 38; no. 6; pp. 1826 - 1836
Main Authors:	Wang, Meng-na, Kuang, Yun, Gong, Li-ying, Hua, Ye, Pei, Qi, Guo, Cheng-xian, Cao, Yu, Huang, Jie, Yang, Guo-ping
Format:	research tables/charts randomized controlled trial Journal Article
Published:	Springer Nature Dec2020
Online Access:	View this record in EBSCOhost